During the past decade, Comprehensive Hematology Oncology conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 1 clinical trials were completed, i.e. on average, 11.1% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 1 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Comprehensive Hematology Oncology" #1 sponsor was "ImmunoVaccine Technologies, Inc. (IMV Inc.)" with 2 trials, followed by "Ayala Pharmaceuticals, Inc," with 1 trials sponsored, "Inspirna, Inc." with 1 trials sponsored, "MediMergent, LLC" with 1 trials sponsored and "MorphoSys AG" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Comprehensive Hematology Oncology" #1 collaborator was "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Institut de Recherches Internationales Servier" with 1 trials as a collaborator and "Iqvia Pty Ltd" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Comprehensive Hematology Oncology" are "Bladder Cancer" (1 trials), "Diffuse Large B-cell Lymphoma" (1 trials), "Endometrial Cancer" (1 trials), "Endometrial Cancer Recurrent" (1 trials) and "Hepatocellular Carcinoma" (1 trials). Many other conditions were trialed in "Comprehensive Hematology Oncology" in a lesser frequency.

Most popular intervention types in "Comprehensive Hematology Oncology" are "Drug" (8 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (3 trials), "DPX-Survivac" (2 trials), "AL101" (1 trials), "Bevacizumab" (1 trials) and "CPA" (1 trials). Other intervention names were less common.

The vast majority of trials in "Comprehensive Hematology Oncology" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Comprehensive Hematology Oncology". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Comprehensive Hematology Oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Comprehensive Hematology Oncology, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".